STAT+: Intellia’s CRISPR-based treatment dramatically reduced patients’ swelling attacks in small trial
Intellia Therapeutics said Sunday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease, saw their swelling attacks — the condition’s hallmark symptom — virtually eliminated for an average of 20 months and counting. The